A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10
|
作者：
Goto, Y. [1 ]
Okada, M. [2 ]
Kijima, T. [3 ]
Aoe, K. [4 ]
Kato, T. [5 ]
Fujimoto, N. [6 ]
Nakagawa, K. [7 ]
Takeda, Y. [8 ]
Hida, T. [9 ]
Kanai, K. [10 ]
Imamura, F. [11 ]
Oizumi, S. [12 ]
Takahashi, T. [13 ]
Takenoyama, M. [14 ]
Tanaka, H. [15 ]
Ohe, Y. [16 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hiroshima Univ, Hiroshima, Japan
[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan
[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[10] Wakayama Med Univ, Wakayama, Japan
[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan
[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan
[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan
[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
malignant pleural mesothelioma; Nivolumab; PD-1;
D O I：
10.1016/j.jtho.2017.09.634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 19.01
引用
收藏
页码：S1883 / S1883
页数：1
相关论文
共 50 条
  • [41] PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)
    Douma, L. -A. H.
    de Gooijer, C. J.
    Noort, V. v. D.
    Lalezari, F.
    de Vries, J. F.
    Vermeulen, M.
    Schilder, B.
    Smesseim, I.
    Baas, P.
    Burgers, J. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S13 - S13
  • [42] NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
    Tanizaki, Junko
    Yonemori, Kan
    Akiyoshi, Kohei
    Minami, Hironobu
    Ueda, Hiroki
    Takiguchi, Yuichi
    Kondoh, Chihiro Nakayama
    Segawa, Yoshihiko
    Takahashi, Shin
    Iwamoto, Yasuo
    Kidera, Yasuhiro
    Fukuoka, Kazuya
    Nakamura, Yasushi
    Chiba, Yasutaka
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
    Calabro, Luana
    Morra, Aldo
    Fonsatti, Ester
    Cutaia, Ornella
    Amato, Giovanni
    Giannarelli, Diana
    Di Giacomo, Anna Maria
    Danielli, Riccardo
    Altomonte, Maresa
    Mutti, Luciano
    Maio, Michele
    LANCET ONCOLOGY, 2013, 14 (11): : 1104 - 1111
  • [44] Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
    Wang, Zhao
    Wang, Jingshi
    Wu, Lin
    Song, Deli
    Pi, Yubo
    Ding, Dawei
    Chen, Yao
    Wang, Xunqiang
    BLOOD, 2024, 144 : 806 - 807
  • [45] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
    Harari, Sergio
    Elia, Davide
    Caminati, Antonella
    Geginat, Jens
    Luisi, Francesca
    Pelosi, Giuseppe
    Specchia, Claudia
    Torre, Olga
    Trevisan, Roberta
    Vasco, Chiara
    Zompatori, Maurizio
    Cassandro, Roberto
    LANCET RESPIRATORY MEDICINE, 2024, 12 (12): : 967 - 974
  • [46] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
    Baas, Paul
    Scherpereel, Arnaud
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Jahan, Thierry
    Antonia, Scott
    Oulkhouir, Youssef
    Bautista, Yolanda
    Cornelissen, Robin
    Greillier, Laurent
    Grossi, Francesco
    Kowalski, Dariusz
    Rodriguez-Cid, Jeronimo
    Aanur, Praveen
    Oukessou, Abderrahim
    Baudelet, Christine
    Zalcman, Gerard
    LANCET, 2021, 397 (10272): : 375 - 386
  • [47] Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).
    Ascierto, Paolo Antonio
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Haanen, John B. A. G.
    Espinosa, Enrique
    Guren, Tormod Kyrre
    Munoz-Couselo, Eva
    Rorive, Andree
    Rutkowski, Piotr
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Hermann, Frank
    Jiang, Joel
    Schadendorf, Dirk
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
    Nakano, T.
    Okada, M.
    Kijima, T.
    Aoe, K.
    Kato, T.
    Fujimoto, N.
    Nakagawa, K.
    Takeda, Y.
    Hida, T.
    Kanai, K.
    Imamura, F.
    Oizumi, S.
    Takahashi, T.
    Takenoyama, M.
    Tanaka, H.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S338 - S338
  • [49] An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas†
    Agulnik, M.
    Yarber, J. L.
    Okuno, S. H.
    von Mehren, M.
    Jovanovic, B. D.
    Brockstein, B. E.
    Evens, A. M.
    Benjamin, R. S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 257 - 263
  • [50] A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma
    van Meerbeeck, JP
    Baas, P
    Debruyne, C
    Smit, EF
    van Klaveren, RJ
    Galdermans, D
    Lentz, MA
    Manegold, C
    Giaccone, G
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (06) : 779 - 783
12345